TargetBeta
C1S
complement C1s · Serine proteases
3 programs in company-led studies act on C1S, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| riliprubart | Sanofi | – | phase 3 | 84 running | – | the company's pipeline |
| SAR446597 | Sanofi | – | phase 2 | 11 running | CFB | the company's pipeline |
| RAY121 | Hoffmann-La Roche | – | phase 1 | 22 running | – | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Anemia, Hemolytic, Autoimmune, 1 program
- Antiphospholipid Syndrome, 1 program
- Geographic Atrophy, 1 program
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 1 program
- Purpura, Thrombocytopenic, Idiopathic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 31, 2027RAY121 · Hoffmann-La Roche · phase 1 · NCT06371417
- Jul 9, 2027riliprubart · Sanofi · phase 3 · NCT06290141
- Oct 13, 2027SAR446597 · Sanofi · phase 2 · NCT07215234
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.